Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

The patent portion of the trade secret case is on hold. Note that the Masimo trade secret lawsuit against Apple is separate ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium. Masimo, SET, Signal Extraction ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

Q3 2024 Earnings Call Transcript November 5, 2024 Masimo Corporation beats earnings expectations. Reported EPS is $0.98, expectations were $0.84. Operator: Ladies and gentlemen, good afternoon, and ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... impact related to a higher proportion of our sales coming from consumables. For our consolidated ...